{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "2859876",
  "DateCompleted": {
    "Year": "1985",
    "Month": "06",
    "Day": "25"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "05",
    "Day": "10"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0306-5251",
      "JournalIssue": {
        "Volume": "19 Suppl 1",
        "Issue": "Suppl 1",
        "PubDate": {
          "Year": "1985"
        }
      },
      "Title": "British journal of clinical pharmacology",
      "ISOAbbreviation": "Br J Clin Pharmacol"
    },
    "ArticleTitle": "The use of benzodiazepines in depression.",
    "Pagination": {
      "StartPage": "31S",
      "EndPage": "35S",
      "MedlinePgn": "31S-35S"
    },
    "Abstract": {
      "AbstractText": [
        "In clinical practice the benzodiazepines are prescribed almost as frequently as the tricyclic antidepressants for the treatment of depression. The therapeutic effects of the benzodiazepines and tricyclic antidepressants in depression have been compared in only 29 double-blind studies. The antidepressants proved overwhelmingly superior with only one study (alprazolam) even suggesting a possible parity of action. A symptom response analysis failed to show any true antidepressant action for the benzodiazepines. No clear indication for the use of a combination of drugs was revealed, although certain symptoms may show a more rapid response initially with combination therapy."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Johnson",
        "ForeName": "D A",
        "Initials": "DA"
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial",
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Br J Clin Pharmacol",
    "NlmUniqueID": "7503323",
    "ISSNLinking": "0306-5251"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Anxiety Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antidepressive Agents, Tricyclic"
    },
    {
      "RegistryNumber": "12794-10-4",
      "NameOfSubstance": "Benzodiazepines"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Anxiety Agents"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antidepressive Agents, Tricyclic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Benzodiazepines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Clinical Trials as Topic"
    },
    {
      "QualifierName": [
        "chemically induced",
        "drug therapy"
      ],
      "DescriptorName": "Depression"
    },
    {
      "QualifierName": [
        "classification",
        "drug therapy",
        "psychology"
      ],
      "DescriptorName": "Depressive Disorder"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Therapy, Combination"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    }
  ]
}